Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany

Journal of Public Health

Volumn 17, Issue 2, 2009, Pages 77-86

  Hillemanns, Peter ^a   Petry, Karl Ulrich ^b   Largeron, Nathalie ^c   McAllister, Ruth ^d   Tolley, Keith ^d   Büsch, Katharina ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Klinikum der Stadt Wolfsburg   (Germany)

^c SANOFI PASTEUR   (France)

^d MAPI VALUES   (United States)

^e Sanofi Pasteur MSD GmbH   (Germany)

Author keywords

Cost effectiveness; Germany; Human papillomavirus (HPV) vaccine

Indexed keywords

RECOMBINANT VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BIOPSY; CANCER PREVENTION; CANCER SCREENING; CHILD; COLPOSCOPY; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MODEL; PAPANICOLAOU TEST; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

EID: 59849112546     PISSN: 09431853     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10389-008-0228-3     Document Type: Article

References (43)

1. Anttila A, Jordan J (2004) Epidemiological guidelines for quality assurance in cervical cancer screening. In: European guidelines for quality assurance in cervical cancer screening, pp 1-70
2. C Bergeron N Largeron R McAllister P Mathevet V Remy 2008 Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France Int J Technol Assess Health Care 24 10 19
3. Bischoff-Everding CH, Reimers W, Hopfenmüller W, Kühn W (2006) Kosten-Nutzen-Effektivitätsanalysen des zytologischen Zervixkarzinomscreenings mittels Markov-Analysen (abstract). 56. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, 2006
4. R Bollmann A Bankfalvi H Griefingholt A Trosic N Speich C Schmitt M Bollmann 2005 Validity of combined cytology and human papillomavirus (HPV) genotyping with adjuvant DNA-cytometry in routine cervical screening: results from 31031 women from the Bonn-region in West Germany Oncol Rep 13 915 922
5. M Brisson N Van de Velde P De Wals MC Boily 2007 Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection CMAJ 177 464 468
6. M Brisson N Van de Velde P De Wals MC Boily 2007 The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada Vaccine 25 5399 5408
7. Brown D (2007) HPV type 6/11/16/18 vaccine: first analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18 (abstract G-1720b). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 17-20 September 2007
8. K Canfell R Barnabas J Patnick V Beral 2004 The predicted effect of changes in cervical screening practice in the UK: results from a modelling study Br J Cancer 91 530 536
9. HW Chesson D Ekwueme P Sasieni E Markowitz 2008 Cost-effectiveness of human papillomavirus vaccination in the United States Emerg Infect Dis 14 244 251
10. GM Clifford JS Smith T Aguado S Franceschi 2003 Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis Br J Cancer 89 101 105
11. GM Clifford RK Rana S Franceschi JS Smith G Gough JM Pimenta 2005 Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer Cancer Epidemiol Biomarkers Prev 14 1157 1164
12. R Crott 2007 Economic analysis of HPV-vaccines: not so simple? Vaccine 25 7717
13. EJ Dasbach EH Elbasha RP Insinga 2006 Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease Epidemiol Rev 28 88 100
14. EJ Dasbach RP Insinga EH Elbasha 2008 The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK BJOG 115 947 956
15. Dutch Health Care Insurance Board (2005) Richtlijnen voor farmaco-economisch onderzoek; evaluatie en actualisatie College voor zorgverzekeringen http://www.cvz.nl/resources/rpt0510-richtlijnen-FEO-tcm28- 17860.pdf. 27 Oct 2005
16. European Commission (2002) Percentage of women reporting specific preventive examinations. Eurobarometer 43.0 and 59.0
17. Federal Statistical Office Germany Statistics (2004) Population: births and deaths. http://www.destatis.de/presse/deutsch/cal-2004. htm#Explanatory%20note.website. 29 Dec 2004
18. SM Garland M Hernandez-Avila CM Wheeler G Perez DM Harper S Leodolter 2007 Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases N Engl J Med 356 1928 1943
19. SJ Goldie M Kohli D Grima MC Weinstein TC Wright FX Bosch E Franco 2004 Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine J Natl Cancer Inst 96 604 615
20. P Hillemanns G Breugelmans F Gieseking S Bénard E Lamure KJ Littlewood KU Petry 2008 Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study BMC Infect Dis 8 76
21. M Jit YH Choi WJ Edmunds 2008 Economic evaluation of human papillomavirus vaccination in the United Kingdom BMJ 337 a769
22. J Karnon J Peters J Platt J Chilcott E McGoogan N Brewer 2004 Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis Health Technol Assess 8 iii1 iii78
23. Krebsregister, Saarland (2003) Annual report of the epidemiological cancer register Saarland for the diagnostic years 1998 to 2000. http://www.krebsregister.saarland.de/. 1 Jul 2003
24. SL Kulasingam S Benard R Barnabas N Largeron ER Myers 2008 Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis Cost Eff Resour Alloc 6 4
25. Lacey C (2008) Continued efficacy of quadrivalent HPV (types 6/11/16/18) L1 VLP vaccine in preventing cervical or external genital disease: 4 years of follow-up. 20th European College of Obstetrics and Gynaecology, Lisbon, 4-8 March 2008
26. MF Mitchell D Schottenfeld G Tortolero-Luna SB Cantor R Richards-Kortum 1998 Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis Obstet Gynecol 91 626 631
27. T Mittendorf KU Petry T Iftner W Greiner JM von der Schulenburg 2003 Economic evaluation of human papillomavirus screening in Germany Eur J Health Econ 4 209 215
28. N Muñoz X Castellsagué AB de González L Gissmann 2006 Chapter 1: HPV in the etiology of human cancer Vaccine 24 Suppl 3 S3/1 S3/10
29. Myers ER, Green S, Lipkus I (2004) Patient preferences for health states related to HPV infection: visual analogue scales vs time trade-off elicitation. Proceedings of the 21st International Papillomavirus Conference, Mexico City, 20-26 February 2004
30. ER Myers DC McCrory K Nanda L Bastian DB Matchar 2000 Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis Am J Epidemiol 151 1158 1171
31. SE Olsson LL Villa RL Costa CA Petta RP Andrade C Malm 2007 Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine Vaccine 25 4931 4939
32. J Paavonen D Jenkins F Bosch P Naud J Salmeron C Wheeler S Chow D Apter H Kitchener X Castellsague N de Carvalho S Skinner D Harper J Hedrick U Jaisamrarn G Limson M Dionne W Quint B Spiessens P Peeters F Struyf S Wieting M Lehtinen M Dubin HPV PATRICIA study group 2007 Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Lancet 369 2161 2170
33. KU Petry S Menton M Menton F van Loenen-Frosch GH de Carvalho B Holz 2003 Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients Br J Cancer 88 1570 1577
34. KU Petry G Breugelmans S Bénard E Lamure KJ Littlewood P Hillemanns 2008 Cost of screening and treatment of cervical dyskaryosis in Germany Eur J Gynaecol Oncol 29 345 349
35. Robert Koch Institute (2007) Statement by the standing committee on vaccinations (STIKO) at the Robert Koch Institute: vaccination against human papilloma virus (HPV) for girls of 12 to 17 years of age-recommendation and explanatory statement. Epidemiology Bulletin 98-103
36. Robert Koch-Institut (2008) Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (ed): Krebs in Deutschland 2003-2004. Häufigkeiten und Trends, 6th edn. Berlin
37. Schenck U, Soost HJ (1995) In Referatband der 13. Fortbildungstagung für klinische Zytologie. Befundwiedergabe in der Zytologie: Münchner Nomenklatur II und Bethesda System 1991. Märkl-Druck, Munich, pp 224-233
38. U Schenck L von Karsa 2000 Cervical cancer screening in Germany Eur J Cancer 36 2221 2226
39. SK Sheriff KU Petry H Ikenberg G Crouse PD Mazonson CC Santas 2007 An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany Eur J Health Econ 8 153 160
40. Siebert U, Muth C, Sroczynski G, Velasco-Garrido M, Gerhardus A, Gibis B (2004) Institute for Technology Assessment. Liquid-based preparation and computer-assisted examination of cervical smears. Clinical effectiveness, economic evaluation and systematic decision analysis. Health Technology Assessment Vol 35. 1-444. Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security. Asgard, St. Augustin
41. U Siebert G Sroczynski P Hillemanns J Engel R Stabenow C Stegmaier 2006 The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany Eur J Public Health 16 185 192
42. FUTURE II Study Group 2007 Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N Engl J Med 356 1915 1927
43. G von Krogh 2001 Management of anogenital warts (condylomata acuminata) Eur J Dermatol 11 598 603